Meta AnalysisID 6570
血脂康胶囊治疗高胆固醇血症：随机临床试验的系统评价和Meta分析
CRD42019132518
To assess the effects of xuezhikang on hypercholesterolaemia.
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 6570
- Evidence Id
- 15128
- Core Evidence Id
- 15128
- Source Meta Analysis Id
- 6552
- Herb2 Meta Analysis Id
- HBMA006552
- Crd Id
- CRD42019132518
- Title
- Xuezhikang capsule for hypercholesterolaemia: a systematic review and meta-analysis of randomized clinical trials
- Review Question
- To assess the effects of xuezhikang on hypercholesterolaemia.
- Study Type Included
- Randomized clinical trials only.
- Condition Being Studied
- Hypercholesterolemia is a condition characterized by high levels of cholesterol in the blood. It is not a disease but a metabolic derangement. The guidelines of the American Heart Association (AHA) and the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) define hypercholesterolaemia as a blood cholesterol concentration of equal to or greater than (≥) 6.22 mmol/L (240 mg/dL) (NECP 2001). Elevated cholesterol in the blood (high blood cholesterol) is due to an increase in the amount of lipoproteins, i.e. particles that carry cholesterol in the bloodstream. There are two major types of cholesterol complexes: HDL (high-density lipoprotein) and LDL (low-density lipoprotein) cholesterol. Hypercholesterolemia usually means high levels of total blood cholesterol or LDL-cholesterol (LDL-C) with normal or low levels of HDL-cholesterol (HDL-C).
- Participant
- Inclusion: adult (18 years or older) participants with hypercholesterolaemia, defined as a mean TC (total cholesterol) level greater than 6.22 mmol/L (240 mg/dL), of any ethnic origin. Exclusion: patients with familial hypercholesterolaemia and secondary hypercholesterolaemia.
- Animal
- Human Disease Modelled
- Intervention
- Xuezhikang was the intervention for this study. Dosage forms include capsules and tablets. We will include all available interventions under this category regardless of the potential mechanisms of action. We will allow any non-traditional medicine-related co-intervention to the experimental or control interventions, as long as all arms of the randomised allocation have received the same co-intervention. The interventions will include: (a) xuezhikang, (b) xuezhikang plus conventional intervention. We will include trials with a minimum treatment duration of at least 30 days, as hypercholesterolaemia is a chronic condition, and the effectiveness may not be detected if the treatment duration is too short.
- Comparator Control
- The comparators will include: (a) no treatment, (b) placebo, non-pharmaceutical interventions compared with (a), conventional interventions compared with (a) or (b).
- Main Outcome
- The effects of cuezhikang capsule in the treatment of hypercholesterolaemia, as assessed by: lipid levels; cardiovascular events; adverse events. Measures of effect Not applicable.
- Outcome Measure
- Additional Outcome
- All-cause mortality; health-related quality of life; changes in body mass index (BMI)/body weight/waist-to-hip ratio (WHR); socioeconomic effects. Measures of effect Not applicable.
- Study Method
- Intervention, Meta-analysis, Systematic review
- Keyword
- Capsules; Cholesterol; Drugs, Chinese Herbal; Humans; Hypercholesterolemia; Hyperlipidemias; Lipids; Medicine, Chinese Traditional; Treatment Outcome
- Contact
- Yu Xin Sun [email protected]
- Organisational Affiliation
- Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- Chinese-Simplified, English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2019-05-04
- Registration Date
- 2019-06-26
- Anticipated Start Date
- 2019-04-01
- Anticipated Completion Date
- 2019-07-09
- Title Cn
- 血脂康胶囊治疗高胆固醇血症：随机临床试验的系统评价和Meta分析
- Title En
- Xuezhikang capsule for hypercholesterolaemia: a systematic review and meta-analysis of randomized clinical trials
- Bilingual Status
- complete